nach oben

Cancer Chemotherapy and Pharmacology

Erschienen in:

09.01.2019 | Original Article

SPP1 inhibition improves the cisplatin chemo-sensitivity of cervical cancer cell lines

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Cisplatin (DDP)-based chemotherapy is a standard strategy for cervical cancer, while chemoresistance remains a huge challenge. In the present study, we aimed to explore the effects of SPP1 on the proliferation and apoptosis rate of the HeLa cervical cancer cell line with cisplatin (DDP) resistance.

Methods

Microarray analysis was employed to select differentially expressed genes in cervical cancer tissues and adjacent tissues. Then, we established a DDP-resistant HeLa cell line (res-HeLa). Western blotting was used to detect SPP1 expression in both tissue and cells. After the transfection with si-SPP1 and pcDNA3.1-SPP1, colony formation and MTT assays were applied to detect cell proliferation changes. Flow cytometry was employed to detect the cell apoptosis rate. Western blotting was performed to verify the activation of PI3K/Akt signal pathway proteins related to DDP resistance.

Results

SPP1 was overexpressed in cervical cancer tissues and cell lines. Compared to normal HeLa cells, expression of SPP1 was significantly enhanced in res-HeLa cells. SPP1 knockdown resulted in repressed proliferation and enhanced apoptosis of res-HeLa cells, which could be reversed by SPP1 overexpression in HeLa cells. Additionally, downregulation of SPP1 improved the DDP sensitivity of HeLa by inhibiting the PI3K/Akt signaling pathway.

Conclusion

SPP1 inhibition could suppress proliferation, induce apoptosis and increase the DDP chemo-sensitivity of HeLa cells.

Zhang YH, Wang JJ, Li M, Zheng HX, Xu L, Chen YG (2016) Matrix metallopeptidase 14 plays an important role in regulating tumorigenic gene expression and invasion ability of HeLa cells. Int J Gynecol Cancer 26(3):600–606. https://doi.org/10.1097/IGC.0000000000000652 CrossRefPubMed

Sun XL, Wang HB, Wang ZQ, Cao TT, Yang X, Han JS, Wu YF, Reilly KH, Wang JL (2017) Effect of transcutaneous electrical stimulation treatment on lower urinary tract symptoms after class III radical hysterectomy in cervical cancer patients: study protocol for a multicentre, randomized controlled trial. BMC Cancer 17(1):416. https://doi.org/10.1186/s12885-017-3387-1 CrossRefPubMedPubMedCentral

Marchetti C, De Felice F, Di Pinto A, Romito A, Musella A, Palaia I, Monti M, Tombolin V, Muzii L, Benedetti Panici P (2018) Survival nomograms after curative neoadjuvant chemotherapy and radical surgery for stage IB2-IIIB cervical cancer. Cancer Res Treat 50(3):768–776. https://doi.org/10.4143/crt.2017.141 CrossRefPubMed

Filippova M, Filippov V, Williams VM, Zhang K, Kokoza A, Bashkirova S, Duerksen-Hughes P (2014) Cellular levels of oxidative stress affect the response of cervical cancer cells to chemotherapeutic agents. Biomed Res Int 2014:574659. https://doi.org/10.1155/2014/574659 CrossRefPubMedPubMedCentral

Gottesman MM (2002) Mechanisms of cancer drug resistance. Annu Rev Med 53:615–627. https://doi.org/10.1146/annurev.med.53.082901.103929 CrossRef

Pariente R, Pariente JA, Rodriguez AB, Espino J (2016) Melatonin sensitizes human cervical cancer HeLa cells to cisplatin-induced cytotoxicity and apoptosis: effects on oxidative stress and DNA fragmentation. J Pineal Res 60(1):55–64. https://doi.org/10.1111/jpi.12288 CrossRef

Agoni L, Basu I, Gupta S, Alfieri A, Gambino A, Goldberg GL, Reddy EP, Guha C (2014) Rigosertib is a more effective radiosensitizer than cisplatin in concurrent chemoradiation treatment of cervical carcinoma, in vitro and in vivo. Int J Radiat Oncol Biol Phys 88(5):1180–1187. https://doi.org/10.1016/j.ijrobp.2013.12.051 CrossRefPubMedPubMedCentral

Wang B, Huang Z, Gao R, Zeng Z, Yang W, Sun Y, Wei W, Wu Z, Yu L, Li Q, Zhang S, Li F, Liu G, Liu B, Leng L, Zhan W, Yu Y, Yang G, Zhou S (2017) Expression of long noncoding RNA urothelial cancer associated 1 promotes cisplatin resistance in cervical cancer. Cancer Biother Radiopharm 32(3):101–110. https://doi.org/10.1089/cbr.2016.2156 CrossRefPubMed

Casagrande N, De Paoli M, Celegato M, Borghese C, Mongiat M, Colombatti A, Aldinucci D (2013) Preclinical evaluation of a new liposomal formulation of cisplatin, lipoplatin, to treat cisplatin-resistant cervical cancer. Gynecol Oncol 131(3):744–752. https://doi.org/10.1016/j.ygyno.2013.08.041 CrossRefPubMed

10.

Liu G, Fan X, Tang M, Chen R, Wang H, Jia R, Zhou X, Jing W, Wang H, Yang Y, Yin F, Wei H, Li B, Zhao J (2016) Osteopontin induces autophagy to promote chemo-resistance in human hepatocellular carcinoma cells. Cancer Lett 383(2):171–182. https://doi.org/10.1016/j.canlet.2016.09.033 CrossRefPubMed

11.

Qin H, Wang R, Wei G, Wang H, Pan G, Hu R, Wei Y, Tang R, Wang J (2018) Overexpression of osteopontin promotes cell proliferation and migration in human nasopharyngeal carcinoma and is associated with poor prognosis. Eur Arch Otorhinolaryngol 275(2):525–534. https://doi.org/10.1007/s00405-017-4827-x CrossRefPubMed

12.

Anborgh PH, Mutrie JC, Tuck AB, Chambers AF (2010) Role of the metastasis-promoting protein osteopontin in the tumour microenvironment. J Cell Mol Med 14(8):2037–2044. https://doi.org/10.1111/j.1582-4934.2010.01115.x CrossRefPubMedPubMedCentral

13.

Ruberti S, Bianchi E, Guglielmelli P, Rontauroli S, Barbieri G, Tavernari L, Fanelli T, Norfo R, Pennucci V, Fattori GC, Mannarelli C, Bartalucci N, Mora B, Elli L, Avanzini MA, Rossi C, Salmoiraghi S, Zini R, Salati S, Prudente Z, Rosti V, Passamonti F, Rambaldi A, Ferrari S, Tagliafico E, Vannucchi AM, Manfredini R (2018) Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients. Leukemia 32(2):438–449. https://doi.org/10.1038/leu.2017.220 CrossRefPubMed

14.

Hao C, Cui Y, Hu MU, Zhi X, Zhang L, Li W, Wu W, Cheng S, Jiang WG (2017) OPN-a splicing variant expression in non-small cell lung cancer and its effects on the bone metastatic abilities of lung cancer cells in vitro. Anticancer Res 37(5):2245–2254. https://doi.org/10.21873/anticanres.11561 CrossRefPubMed

15.

Kijewska M, Kocyk M, Kloss M, Stepniak K, Korwek Z, Polakowska R, Dabrowski M, Gieryng A, Wojtas B, Ciechomska IA, Kaminska B (2017) The embryonic type of SPP1 transcriptional regulation is re-activated in glioblastoma. Oncotarget 8(10):16340–16355. https://doi.org/10.18632/oncotarget.14092 CrossRefPubMed

16.

Chang H, Li X, Cai Q, Li C, Tian L, Chen J, Xing X, Gan Y, Ouyang W, Yang Z (2017) The PI3K/Akt/mTOR pathway is involved in CVB3-induced autophagy of HeLa cells. Int J Mol Med 40(1):182–192. https://doi.org/10.3892/ijmm.2017.3008 CrossRefPubMedPubMedCentral

17.

Shu XR, Wu J, Sun H, Chi LQ, Wang JH (2015) PAK4 confers the malignance of cervical cancers and contributes to the cisplatin-resistance in cervical cancer cells via PI3K/AKT pathway. Diagn Pathol 10:177. https://doi.org/10.1186/s13000-015-0404-z CrossRefPubMedPubMedCentral

18.

Song J, Li Y (2017) miR-25-3p reverses epithelial-mesenchymal transition via targeting Sema4C in cisplatin-resistance cervical cancer cells. Cancer Sci 108(1):23–31. https://doi.org/10.1111/cas.13104 CrossRefPubMed

19.

Johanneson B, Chen D, Enroth S, Cui T, Gyllensten U (2014) Systematic validation of hypothesis-driven candidate genes for cervical cancer in a genome-wide association study. Carcinogenesis 35(9):2084–2088. https://doi.org/10.1093/carcin/bgu125 CrossRefPubMed

20.

Giacopelli F, Marciano R, Pistorio A, Catarsi P, Canini S, Karsenty G, Ravazzolo R (2004) Polymorphisms in the osteopontin promoter affect its transcriptional activity. Physiol Genom 20(1):87–96. https://doi.org/10.1152/physiolgenomics.00138.2004 CrossRef

21.

Sharma P, Kumar S, Kundu GC (2010) Transcriptional regulation of human osteopontin promoter by histone deacetylase inhibitor, trichostatin A in cervical cancer cells. Mol Cancer 9:178. https://doi.org/10.1186/1476-4598-9-178 CrossRefPubMedPubMedCentral

22.

Cho H, Hong SW, Oh YJ, Kim MA, Kang ES, Lee JM, Kim SW, Kim SH, Kim JH, Kim YT, Lee K (2008) Clinical significance of osteopontin expression in cervical cancer. J Cancer Res Clin Oncol 134(8):909–917. https://doi.org/10.1007/s00432-007-0351-5 CrossRefPubMed

23.

Song JY, Lee JK, Lee NW, Jung HH, Kim SH, Lee KW (2008) Microarray analysis of normal cervix, carcinoma in situ, and invasive cervical cancer: identification of candidate genes in pathogenesis of invasion in cervical cancer. Int J Gynecol Cancer 18(5):1051–1059. https://doi.org/10.1111/j.1525-1438.2007.01164.x CrossRefPubMed

24.

Li F, Guo Y, Han L, Duan Y, Fang F, Niu S, Ba Q, Zhu H, Kong F, Lin C, Wen X (2012) In vitro and in vivo growth inhibition of drug-resistant ovarian carcinoma cells using a combination of cisplatin and a TRAIL-encoding retrovirus. Oncol Lett 4(6):1254–1258. https://doi.org/10.3892/ol.2012.926 CrossRefPubMedPubMedCentral

25.

Yang H, Wu XL, Wu KH, Zhang R, Ju LL, Ji Y, Zhang YW, Xue SL, Zhang YX, Yang YF, Yu MM (2016) MicroRNA-497 regulates cisplatin chemosensitivity of cervical cancer by targeting transketolase. Am J Cancer Res 6(11):2690–2699PubMedPubMedCentral

26.

Qian C, Li P, Yan W, Shi L, Zhang J, Wang Y, Liu H, You Y (2015) Downregulation of osteopontin enhances the sensitivity of glioma U251 cells to temozolomide and cisplatin by targeting the NF-kappaB/Bcl2 pathway. Mol Med Rep 11(3):1951–1955. https://doi.org/10.3892/mmr.2014.2951 CrossRefPubMed

27.

Gu T, Ohashi R, Cui R, Tajima K, Yoshioka M, Iwakami S, Sasaki S, Shinohara A, Matsukawa T, Kobayashi J, Inaba Y, Takahashi K (2009) Osteopontin is involved in the development of acquired chemo-resistance of cisplatin in small cell lung cancer. Lung Cancer 66(2):176–183. https://doi.org/10.1016/j.lungcan.2009.02.004 CrossRefPubMed

28.

Li Y, Cui N, Zheng PS, Yang WT (2017) BMX/Etk promotes cell proliferation and tumorigenicity of cervical cancer cells through PI3K/AKT/mTOR and STAT3 pathways. Oncotarget 8(30):49238–49252. https://doi.org/10.18632/oncotarget.17493 CrossRefPubMedPubMedCentral

29.

Liao S, Xiao S, Zhu G, Zheng D, He J, Pei Z, Li G, Zhou Y (2014) CD38 is highly expressed and affects the PI3K/Akt signaling pathway in cervical cancer. Oncol Rep 32(6):2703–2709. https://doi.org/10.3892/or.2014.3537 CrossRefPubMed

30.

Kumar V, Behera R, Lohite K, Karnik S, Kundu GC (2010) p38 kinase is crucial for osteopontin-induced furin expression that supports cervical cancer progression. Cancer Res 70(24):10381–10391. https://doi.org/10.1158/0008-5472.CAN-10-1470 CrossRefPubMed

Titel: SPP1 inhibition improves the cisplatin chemo-sensitivity of cervical cancer cell lines
Publikationsdatum: 09.01.2019
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 4/2019
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-018-3759-5

Springer Medizin

SPP1 inhibition improves the cisplatin chemo-sensitivity of cervical cancer cell lines

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2019

Pharmacokinetic and cytokine profiles of melanoma patients with dabrafenib and trametinib-induced pyrexia

Cyclophosphamide dose adjustment based on body weight and albuminemia in elderly patients treated with R-mini-CHOP

Analysis of SPARC and TUBB3 as predictors for prognosis in esophageal squamous cell carcinoma receiving nab-paclitaxel plus cisplatin neoadjuvant chemotherapy: a prospective study

d-Dimer increase: an unfavorable factor for patients with primary liver cancer treated with TACE

Changes in skeletal muscle area and lean body mass during pazopanib vs sunitinib therapy for metastatic renal cancer

Effect of aprepitant administration on CINV caused by cisplatin multi-day chemotherapy and pharmacokinetics of docetaxel

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie